Statins as Adjunctive Therapy in the Management of Hypertension
Authors:
- 30 May 2010
- journal article
- review article
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 12 (5) , 349-354
Abstract
The effective optimization of the modifiable risk factors for the development of atherosclerosis is the cornerstone preventive cardiology. Risk factor clustering has been demonstrated to occur in a higher prevalence than would be expected by chance alone. The common cardiovascular risk factors frequently share metabolic pathways. Inflammation and oxidative stress are demonstrable in the major cardiovascular risk factors. Hypertension and dyslipidemia frequently co-exist in an individual. The advent of statin therapy has allowed optimization of the lipid profile and achievement of therapeutic goals advocated by the Adult Treatment Panel of the National Cholesterol Education Program. Statin therapy has been demonstrated to exhibit a wide variety of nonlipid or pleiotropic effects. Observational studies have demonstrated that statin therapy may cause a small but statistically significant alteration of blood pressure. Prospective clinical trials have demonstrated that statin therapy reduces this cardiovascular risk in both hypertensive and normotensive individuals. The potential role of statin therapy in blood pressure reduction is compatible with several pleiotropic mechanisms of statin therapy. However, a significant body of data from prospective, well-designed, controlled clinical trials that have analyzed the effect of statin therapy on blood pressure as the primary end point is lacking. This review examines the observational relationship between hypertension and dyslipidemia, the potential mechanisms by which statin therapy may lower blood pressure, and selected clinical trial data.Keywords
This publication has 38 references indexed in Scilit:
- C-reactive protein implications in new-onset hypertension in a healthy population initially aged 65 years: the Proof studyJournal Of Hypertension, 2009
- C-reactive protein stimulates superoxide anion release and tissue factor activity in vivoAtherosclerosis, 2009
- C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate RiskJACC, 2007
- Simvastatin inhibits lipopolysaccharide-induced tumor necrosis factor-α expression in neonatal rat cardiomyocytes: The role of reactive oxygen speciesBiochemical and Biophysical Research Communications, 2006
- Statins: another class of antihypertensive agents?Journal of Human Hypertension, 2006
- PLEIOTROPIC EFFECTS OF STATINSAnnual Review of Pharmacology and Toxicology, 2005
- Vascular Remodeling in HypertensionHypertension, 2001
- Disruption of the endothelial nitric oxide synthase gene: effect on vascular response to injuryThe American Journal of Cardiology, 1998
- Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.Journal of Clinical Investigation, 1998
- Hyperinsulinemia and Dyslipidemia in Non-Obese, Normotensive Offspring of Hypertensive Parents in Northern IndiaBlood Pressure, 1998